Crossmark

Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR)

Crossref DOI link: https://doi.org/10.1186/s12885-022-09623-z

Published Online: 2022-05-12

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Dos Santos, Mélanie

Lequesne, Justine

Leconte, Alexandra

Corbinais, Stéphane

Parzy, Aurélie

Guilloit, Jean-Marc

Varatharajah, Sharmini

Brachet, Pierre-Emmanuel

Dorbeau, Marine

Vaur, Dominique

Weiswald, Louis-Bastien

Poulain, Laurent

Le Gallic, Corentin

Castera-Tellier, Marie

Galais, Marie-Pierre

Clarisse, Bénédicte
License Information

Text and Data Mining valid from 2022-05-12

Version of Record valid from 2022-05-12
More Information

Article History

Received: 7 April 2022

Accepted: 29 April 2022

First Online: 12 May 2022

Declarations

:

: This study has received ethical approval from the <i>Comité de Protection des Personnes EST IV</i> (N°EudraCT: 2020–004497-21) and from National Agency for Medical and Health products Safety (Reference: 2020–12-00012_2020-004497–21) in January 2021. All patients will be proposed to participate by the medical oncologists, gastroenterologists or digestive surgeons, who will give them an information file. All patients will give their written informed consent before any study-related assessment start.

: Not applicable.

: Novartis provided Spartalizumab.

Document is current

Any future updates will be listed below